Avelumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Avelumab" in English language version.

refsWebsite

Global rank English rank

7web.archive.org

1^st place

5fda.gov

447^th place

338^th place

5nih.gov

4^th place

3europa.eu

68^th place

117^th place

2drugs.com

399^th place

333^rd place

2canada.ca

1,712^th place

1,063^rd place

2doi.org

2^nd place

1hres.ca

low place

1pfizer.com

low place

1biopharmadive.com

low place

biopharmadive.com

Pfizer, Merck KGaA fourth to market with PD-1/L1 inhibitor

canada.ca

"Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

doi.org

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–44. doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.{{cite journal}}: CS1 maint: overridden setting (link)
Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. (January 2018). "Updated efficacy of avelumab in participants with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial". Journal for Immunotherapy of Cancer. 6 (1): 7. doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.{{cite journal}}: CS1 maint: overridden setting (link)

drugs.com

"Avelumab (Bavencio) Use During Pregnancy". Drugs.com. 29 May 2019. Retrieved 2 August 2020.
"Bavencio Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists, Inc. 27 January 2020. Retrieved 2 August 2020.

europa.eu

ema.europa.eu

"Bavencio EPAR". European Medicines Agency (EMA). 18 September 2017. Retrieved 15 June 2024.
"Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer" (PDF). European Medicines Agency. 9 January 2017. Archived from the original (PDF) on 5 August 2017. Retrieved 29 April 2017.
"Bavencio: EPAR - Product Information" (PDF). European Medicines Agency. 18 September 2017. Archived from the original (PDF) on 17 June 2018. Retrieved 23 February 2018.

fda.gov

"FDA approves first treatment for rare form of skin cancer". U.S. Food and Drug Administration (FDA) (Press release). 23 March 2017. Archived from the original on 11 December 2019. Retrieved 2 August 2020. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to avelumab for urothelial carcinoma". U.S. Food and Drug Administration. 9 May 2017. Archived from the original on 28 September 2019. Retrieved 30 September 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves avelumab plus axitinib for renal cell carcinoma". U.S. Food and Drug Administration (FDA). 14 May 2019. Retrieved 29 September 2020.
"FDA approves avelumab for urothelial carcinoma maintenance treatment". U.S. Food and Drug Administration (FDA). 30 June 2020. Archived from the original on 3 August 2020. Retrieved 29 September 2020.
"FDA approves avelumab for urothelial carcinoma maintenance treatment". U.S. Food and Drug Administration (FDA). 30 June 2020. Archived from the original on 3 August 2020. Retrieved 2 August 2020. This article incorporates text from this source, which is in the public domain.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Bavencio". 23 October 2014.

nih.gov

ncbi.nlm.nih.gov

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–44. doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.{{cite journal}}: CS1 maint: overridden setting (link)
Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. (January 2018). "Updated efficacy of avelumab in participants with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial". Journal for Immunotherapy of Cancer. 6 (1): 7. doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.{{cite journal}}: CS1 maint: overridden setting (link)

pubmed.ncbi.nlm.nih.gov

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–44. doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.{{cite journal}}: CS1 maint: overridden setting (link)
Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. (January 2018). "Updated efficacy of avelumab in participants with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial". Journal for Immunotherapy of Cancer. 6 (1): 7. doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Bavencio- avelumab injection, solution, concentrate". DailyMed. 2 July 2020. Retrieved 2 August 2020.

pfizer.com

Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet" (PDF). Archived from the original (PDF) on 17 May 2017. Retrieved 2 December 2015.

web.archive.org

"FDA approves first treatment for rare form of skin cancer". U.S. Food and Drug Administration (FDA) (Press release). 23 March 2017. Archived from the original on 11 December 2019. Retrieved 2 August 2020. This article incorporates text from this source, which is in the public domain.
"Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer" (PDF). European Medicines Agency. 9 January 2017. Archived from the original (PDF) on 5 August 2017. Retrieved 29 April 2017.
"Bavencio: EPAR - Product Information" (PDF). European Medicines Agency. 18 September 2017. Archived from the original (PDF) on 17 June 2018. Retrieved 23 February 2018.
Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet" (PDF). Archived from the original (PDF) on 17 May 2017. Retrieved 2 December 2015.
"FDA grants accelerated approval to avelumab for urothelial carcinoma". U.S. Food and Drug Administration. 9 May 2017. Archived from the original on 28 September 2019. Retrieved 30 September 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves avelumab for urothelial carcinoma maintenance treatment". U.S. Food and Drug Administration (FDA). 30 June 2020. Archived from the original on 3 August 2020. Retrieved 29 September 2020.
"FDA approves avelumab for urothelial carcinoma maintenance treatment". U.S. Food and Drug Administration (FDA). 30 June 2020. Archived from the original on 3 August 2020. Retrieved 2 August 2020. This article incorporates text from this source, which is in the public domain.